Czech National Bank Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Czech National Bank raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,088 shares of the medical research company’s stock after buying an additional 571 shares during the quarter. Czech National Bank’s holdings in Charles River Laboratories International were worth $2,047,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CRL. Empirical Finance LLC boosted its position in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after acquiring an additional 53 shares during the period. American Trust boosted its holdings in Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 54 shares during the period. OLD National Bancorp IN grew its position in shares of Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares in the last quarter. M&T Bank Corp grew its position in shares of Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in shares of Charles River Laboratories International by 4.5% in the third quarter. Massmutual Trust Co. FSB ADV now owns 1,842 shares of the medical research company’s stock worth $363,000 after purchasing an additional 79 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. UBS Group boosted their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Finally, Bank of America decreased their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $165.60 on Friday. The company has a 50-day simple moving average of $192.56 and a two-hundred day simple moving average of $198.95. Charles River Laboratories International, Inc. has a 12-month low of $160.85 and a 12-month high of $275.00. The firm has a market cap of $8.47 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 6.62 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.72 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).